Category Archives: dementia

A Peek Inside the Brains of ‘Super-Agers’

New research explores why some octogenarians have exceptional memories.

When it comes to aging, we tend to assume that cognition gets worse as we get older. Our thoughts may slow down or become confused, or we may start to forget things, like the name of our high school English teacher or what we meant to buy at the grocery store.

But that’s not the case for everyone.

For a little over a decade, scientists have been studying a subset of people they call “super-agers.” These individuals are age 80 and up, but they have the memory ability of a person 20 to 30 years younger.

Most research on aging and memory focuses on the other side of the equation — people who develop dementia in their later years. But, “if we’re constantly talking about what’s going wrong in aging, it’s not capturing the full spectrum of what’s happening in the older adult population,” said Emily Rogalski, a professor of neurology at the University of Chicago, who published one of the first studies on super-agers in 2012.

LIVING with DEMENTIA

Cases of dementia are rising around the world. The disease has no cure, but caregivers and families are finding innovative ways for patients to live with dignity

“Today an estimated 57 million people globally have dementia—about 12 percent live in the United States—and cases are projected to rise to 153 million by 2050. By then, medical and caregiving costs are expected to reach $16.9 trillion worldwide. Numerous factors are contributing to the increase, most notably a growing older population; a rise in risk factors like obesity and diabetes; and worsening air pollution, which, studies show, damages brain health.”

https://apple.news/ACRTM12IUTOCTLOmNu9-6Ng

Alzheimer’s Disease — Managing Stages of Dementia

In this Double Take video from the New England Journal of Medicine, Drs. Nathaniel Chin and Stephen Salloway define the stages of dementia and the effect of each stage on the activities of daily living. They also discuss ways to support persons with Alzheimer’s disease at every stage of the disease, including available medications and potential side effects. The video also emphasizes the importance of advance care planning for persons with mild cognitive impairment and providing support to care partners.

https://www.nejm.org/doi/full/10.1056/NEJMp2310177

F.D.A. Delays Action on new Alzheimer’s Drug

Crazy that FDA fast-tracked the first novel drug for Alzheimer’s but now the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy of Eli Lilly’s donanemab.

The decision is likely to surprise many Alzheimer’s experts, doctors and patients who had expected the medication would soon be on the market. The F.D.A.’s move was startling to the company, which had been planning for the agency to greenlight the drug during the first quarter of this year.

“We were not expecting this,” Anne White, an executive vice president of Lilly and president of its neuroscience division, said in an interview. She said that while the F.D.A. often calls on such independent advisory committees when it has questions about drugs, it was unusual to do so “at the end of the review cycle and beyond the action date that the F.D.A. had given us.”

APOE Association with Alzheimer’s Explained

Alzheimer’s disease, the most prevalent form of dementia, typically occurs after the age of 65. A significant genetic factor associated with this type of Alzheimer’s at a younger age is a gene called apolipoprotein E (APOE), which comes in three common variations:

APOE e2: This form is the least common and is associated with a reduced risk of Alzheimer’s disease.

APOE e4: More prevalent than e2, this gene variant increases the risk of Alzheimer’s and is linked to a more severe form of the disease.

APOE e3: The most common variant, it does not seem to significantly affect the risk of developing Alzheimer’s.

It’s important to note that genes are not the sole determining factor in Alzheimer’s disease risk.

Each individual inherits one copy of the APOE gene from each parent. Having at least one APOE e4 gene doubles or triples the risk of developing Alzheimer’s disease. Some individuals inherit two APOE e4 genes, one from each parent, which substantially increases the risk, by about eight- to twelvefold.